The intraoperative effect of pentoxifylline on the inflammatory process and leukocytes in cardiac surgery patients undergoing cardiopulmonary bypass

Perfusion

Volumn 20, Issue 1, 2005, Pages 45-51

  Çaǧli, Kerim ^a,d   Ulaş, Mahmut Mustafa ^a   Özişik, Kanat ^b   Kale, Arzum ^a   Bakuy, Vedat ^a   Emir, Mustafa ^a   Balci, Mustafa ^a   Topbaş, Murat ^c   Şener, Erol ^a   Taşdemir, Oǧuz ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b Numune Teaching and Research Hospital   (Turkey)

^c KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^d NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; C REACTIVE PROTEIN; CARDIOPLEGIC AGENT; CEFAZOLIN; DIAZEPAM; FENTANYL; HEPARIN; INTERLEUKIN 6; MORPHINE; PANCURONIUM; PENTOXIFYLLINE; PLACEBO; PROTAMINE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANESTHESIA INDUCTION; ARTICLE; BASOPHIL; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CELL TYPE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG RESPONSE; EOSINOPHIL; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

C-REACTIVE PROTEIN; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTRAOPERATIVE PERIOD; LEUKOCYTE COUNT; LEUKOCYTES; MIDDLE AGED; PENTOXIFYLLINE; PLACEBOS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 20044378097     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1191/0267659105pf779oa     Document Type: Article

References (26)

1. Edmunds LH Jr. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1998; 66: S12-16.
2. Asimakopoulos G, Smith PLC, Ratnatunga CP, Taylor KM. Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg 1999; 68: 1107-15.
3. Downing SW, Edmunds LH, Jr. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 1236-43.
4. Wachtfogel YT, Kucich U, Greenplate J et al. Human neutrophil degranulation during extracorporeal circulation. Blood 1987; 69: 324-30.
5. Rinder CS, Bonan JL, Rinder HM et al. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992; 79: 1201-205.
6. Gadaleta D, Fahey AL, Verma M et al. Neutrophil leukotriene generation increases after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 108: 642-47.
7. Butler J, Parker D, Pillai R et al. Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor. J Thorac Cardiovasc Surg 1993; 105: 25-30.
8. Casey LC. Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Ann Thorac Surg 1993; 56: S92-96.
9. Gott JP, Cooper WA, Schmidt FE et al. Modifying risk of extracorporeal circulation: trial of four antiinflammatory strategies. Ann Thorac Surg 1998; 66: 747-54.
10. Royston D. The inflammatory response and extracorporeal circulation. J Cardiothorac Vasc Anesth 1997; 11: 341-54.
11. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34: 50-97.
12. Schade UF. Pentoxifylline increases survival in murine endotoxic shock and decreases formation of tumor necrosis factor. Circ Shock 1990; 31: 171-81.
13. Jansen NJG, van Oeveren W, Gu YJ et al. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 744-48.
14. Hennein HA, Ebba H, Rodriguez JL et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994; 108: 626-35.
15. Pollice PF, Rosier RN, Looney RJ et al. Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes: a potential treatment for aseptic loosening of total joint components. J Bone Joint Surg Am 2001; 83: 1057-61.
16. Witkamp R, Monshouwer M. Signal transduction in inflammatory processes, current and future therapeutic targets: a mini review. Vet Q 2000; 22: 11-16.
17. Miller BE, Levy JH. The inflammatory response to cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11: 355-66.
18. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253-78.
19. Kawamura T, Wakusawa R, Okada K, Inada S. Evaluation of cytokines during open heart surgery with cardiopulmonary bypass: participation of interleukin-8 and 6 in reperfusion injury. Can J Anaesth 1993; 40: 1016-21.
20. Steinberg JB, Kapelanski DP, Olson J, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 106: 1008-16.
21. Gale SC, Hokama JY, Ritter LS et al. Pentoxifylline reduces coronary leukocyte accumulation early in reperfusion after cold ischemia. Ann Thorac Surg 2001; 71: 1305-11.
22. Pasquier C, Franzini EAZ, Kaouadji M, Hakim J. Gamma pulse radiolysis study of pentoxifylline, a methylxanthine. Int J Rad Biol 1991; 60: 433-37.
23. Wehlin L, Vedin J, Vaage J, Lundahl J. Activation of complement and leukocyte receptors during on- and off-pump coronary artery bypass surgery. Eur J Cardiothorac Surg 2004; 25: 35-42.
24. Staubach KH, Schroder J, Stuber F et al. Effect of pentoxifylline in severe sepsis: a double-blind, placebo-controlled study. Arch Surg 1998; 133: 94-100.
25. Sigurdsson GH, Youssef H. Effects of pentoxifylline on hemodynamics, gas exchange and multiple organ platelet sequestration in experimental endotoxic shock. Acta Anaesthesiol Scand 1993; 37 396-403.
26. Levi M, ten Cate H, Bauer KA et al. Inhibition of endotoxin induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-20.